Strasbourg cohort of people with adrenal cortical carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort compiles retrospective and prospective clinical, imaging, biochemical and histopathologic data from adults diagnosed with adrenal cortical carcinoma and followed at Strasbourg University Hospital between January 1, 2000 and May 31, 2025. Inclusion requires histopathologic confirmation of the adrenal cortical tumor and excludes tumors later reclassified as non-ACC. Collected data will include Weiss score, Ki-67, hormonal secretion status, imaging features, treatments and outcomes. The work is purely descriptive and aims to define disease patterns and prognostic markers to inform future research and clinical decisions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult subject (≥ 18 years old)
* Subjects followed at Strasbourg University Hospital for adrenal cortical carcinoma diagnosed between January 1, 2000, and May 31, 2025

Exclusion Criteria:

\- Tumor reclassified as non-SCC by histopathology

Where it's running

• Service d'Endocrinologie, Diabétologie, Nutrition - CHU de Strasbourg - France
  Strasbourg, France Recruiting

Study contacts

• Study coordinator: Philippe BALTZINGER, MD
• Email: philippe.baltzinger@chru-strasbourg.fr
• Phone: 33 3 88 12 75 82

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cemiplimab maintenance for advanced adrenocortical carcinoma

  This trial will test whether giving cemiplimab as maintenance immunotherapy after first-line EDP-M chemotherapy can delay progression in adults with advanced adrenocortical carcinoma who achieved a response or stable disease.

  Recruiting Phase 2 Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · Brescia, Brescia · NCT07085572

• Combining PD-1 inhibitor with Apatinib and Mitotane for advanced adrenal cancer treatment

  This study is testing a new combination of three medications to see if it can help people with advanced adrenal cancer who haven't had treatment yet.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT06831175

• Personalized mRNA vaccine for advanced endocrine tumors

  This study is testing a personalized mRNA vaccine to see if it can help patients with advanced endocrine tumors who haven't had success with standard treatments.

  Recruiting Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT06141369

• Cabozantinib plus pembrolizumab for advanced or unresectable adrenal cortical cancer

  This trial tests whether adding cabozantinib to pembrolizumab can shrink or control advanced, metastatic, or unresectable adrenal cortical cancer.

  Recruiting at 2 sites Phase 2 Emory University · Atlanta, Georgia and 1 other locations · NCT06006013

• Combining PDS01ADC with targeted liver chemotherapy for certain cancers

  This study is testing if a new cancer treatment that combines an immune booster with targeted liver chemotherapy can help people with certain advanced cancers feel better and live longer.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05286814

• Preoperative targeted radiation before surgery for recurrent abdominal adrenocortical carcinoma

  This study tests giving a short course of focused external beam radiation before surgery in adults whose adrenocortical cancer has come back and appears removable.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06487481

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.